# PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

> **NCT04556617** · PHASE1,PHASE2 · TERMINATED · sponsor: **Opna Bio LLC** · enrollment: 19 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** PLX2853 20 mg
- **DRUG:** Olaparib
- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone
- **DRUG:** PLX2853 40 mg
- **DRUG:** PLX2853 80 mg

## Key facts

- **NCT ID:** NCT04556617
- **Lead sponsor:** Opna Bio LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-21
- **Primary completion:** 2022-05-24
- **Final completion:** 2022-05-24
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** study terminated due to business realignment
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04556617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04556617, "PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04556617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*